A Preclinical Systematic Review of Ginsenoside-Rg1 in Experimental Parkinson's Disease

Oxidative Medicine and Cellular Longevity

Volumn 2017, Issue , 2017, Pages

  Song, Liang ^a,b   Xu, Meng Bei ^a   Zhou, Xiao Li ^a   Zhang, Dao Pei ^b   Zhang, Shu Ling ^b   Zheng, Guo Qing ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b ZHENGZHOU PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANTS; NEURODEGENERATIVE DISEASES;

ANTI-APOPTOTIC EFFECTS; DIFFERENT MECHANISMS; ELECTRONIC DATABASE; NEUROPROTECTIVE EFFECTS; PARKINSON'S DISEASE; POSSIBLE MECHANISMS; PROTEIN EXPRESSIONS; SYSTEMATIC REVIEW;

PHARMACODYNAMICS;

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIOXIDANT; CASPASE 3; CHLORAL HYDRATE; GINSENOSIDE RG 1; MESSENGER RNA; NOOTROPIC AGENT; OXIDOPAMINE; PENTOBARBITAL; PROTEIN C JUN; TYROSINE 3 MONOOXYGENASE; GINSENOSIDE; NEUROPROTECTIVE AGENT;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; DOPAMINERGIC NERVE CELL; EXPERIMENTAL PARKINSONISM; META ANALYSIS (TOPIC); NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PRECLINICAL STUDY; PROTEIN EXPRESSION; REVIEW; ROTAROD TEST; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; SYSTEMATIC REVIEW; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; PARKINSON DISEASE;

DIAGNOSIS; DISEASES; MEDICINE; MODELS;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GINSENOSIDES; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 85016568801     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2017/2163053     Document Type: Review

References (54)

1. G. E. Alexander, "Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder," Dialogues in Clinical Neuroscience, vol. 6, no. 3, pp. 259-280, 2004.
2. M. Löhle and H. Reichmann, "Clinical neuroprotection in Parkinson's disease-still waiting for the breakthrough," Journal of the Neurological Sciences, vol. 289, no. 1-2, pp. 104-114, 2010.
3. P. Calabresi, M. D. Filippo, V. Ghiglieri, N. Tambasco, and B. Picconi, "Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap," The Lancet Neurology, vol. 9, no. 11, pp. 1106-1117, 2010.
4. T. A. Zesiewicz and M. L. Evatt, "Potential influences of complementary therapy on motor and non-motor complications in parkinsons disease," CNS Drugs, vol. 23, no. 10, pp. 817-835, 2009.
5. G. Zheng, "Therapeutic History of Parkinson's Disease in Chinese Medical Treatises," The Journal of Alternative and Complementary Medicine, vol. 15, no. 11, pp. 1223-1230, 2009.
6. S.-Y. Nah, D.-H. Kim, and H. Rhim, "Ginsenosides: are any of them candidates for drugs acting on the central nervous system?" CNS Drug Reviews, vol. 13, no. 4, pp. 381-404, 2007.
7. J. Lu, Q. Yao, and C. Chen, "Ginseng compounds: an update on theirmolecular mechanisms and medical applications," Current Vascular Pharmacology, vol. 7, no. 3, pp. 293-302, 2009.
8. K. Leung and A. Wong, "Pharmacology of ginsenosides: a literature review," Chinese Medicine, vol. 5, no. 1, article no. 20, 2010.
9. B. Jiang, Z. Xiong, J. Yang et al., "Antidepressant-like effects of ginsenoside Rg1 are due to activation of the BDNF signalling pathway and neurogenesis in the hippocampus," British Journal of Pharmacology, vol. 166, no. 6, pp. 1872-1887, 2012.
10. H. J. Kim, P. Kim, and C. Y. Shin, "A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system," Journal of Ginseng Research, vol. 37, no. 1, pp. 8-29, 2013.
11. K. Radad, G. Gille, L. Liu, and W.-D. Rausch, "Use of ginseng in medicine with emphasis on neurodegenerative disorders," Journal of Pharmacological Sciences, vol. 100, no. 3, pp. 175-186, 2006.
12. H. B. van der Worp, D. W. Howells, E. S. Sena et al., "Can animal models of disease reliably informhuman studies?" PLoS medicine, vol. 7, no. 3, Article ID e1000245, 2010.
13. M. R. Macleod, T. O'Collins, D. W. Howells, and G.A. Donnan, "Pooling of animal experimental data reveals influence of study design and publication bias," Stroke, vol. 35, no. 5, pp. 1203-1208, 2004.
14. H. M. Vesterinen, E. S. Sena, K. J. Egan et al., "Meta-analysis of data from animal studies: a practical guide," Journal of Neuroscience Methods, vol. 221, pp. 92-102, 2014.
15. H. W. E. Zhang, Z. X. I. Lin, C. Xu, C. Leung, and L. S. U. Chan, "Astragalus (a traditional Chinese medicine) for treating chronic kidney disease," The Cochrane Database of Systematic Reviews, vol. 10, Article IDCD008369, 2014.
16. Y. Heng, Q.-S. Zhang, Z. Mu, J.-F. Hu, Y.-H. Yuan, and N.- H. Chen, "Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mousemodel by targeting α-synuclein abnormalities in the substantia nigra," Toxicology Letters, vol. 243, pp. 7-21, 2016.
17. W. Jiang, Z. Wang, Y. Jiang, M. Lu, and X. Li, "Ginsenoside Rg1 ameliorates motor function in an animal model of Parkinson's disease," Pharmacology, vol. 96, no. 1-2, pp. 25-31, 2015.
18. T.-T. Zhou, G. Zu, X. Wang et al., "Immunomodulatory and neuroprotective effects of ginsenoside Rg1 in the MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) -induced mouse model of Parkinson's disease," International Immunopharmacology, vol. 29, no. 2, pp. 334-343, 2015.
19. X.-C. Chen, Y.-C. Zhou, Y. Chen, Y.-G. Zhu, F. Fang, and L.- M. Chen, "Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress," Acta Pharmacologica Sinica, vol. 26, no. 1, pp. 56-62, 2005.
20. X.-C. Chen, Y. Chen, Y.-G. Zhu, F. Fang, and L.-M. Chen, "Protective effect of ginsenoside Rg1 against MPTP-induced apoptosis in mouse substantia nigra neurons," Acta Pharmacologica Sinica, vol. 23, no. 9, pp. 829-834, 2002.
21. J. B. Wei, F. Yang, and S. X. Wang, "Influence of Ginsenoside Rg1 on expression of erythropoietin-producing hepatocellular cell line A4 in substantia nigras of mice with Parkinson's disease induced by 1-methy-4-pheny-1,2,3,6-tetrahy-dro-pyrdine," Journal of Xinxiang Medical University, vol. 32, no. 5, pp. 404-407, 2015.
22. S. X. Wang, F. X. Zhu, P. Y. Li, and Y. Duan, "Effects of ginsenoside Rgl on apoptosis of dopamine neurons, expression l, TH and P-c-Jun in substantia nigra of mice with Parkinson," Journal of Zhengzhou University, vol. 50, no. 2, pp. 176-180, 2015.
23. F. X. Zhu, Y. Duan, P. Y. Li, and S. X. Wang, "Effect of ginsenoside Rg1 on the expressions of tyrosine hydroxylase, ephrin B2 and phosphorylated c-Jun in substantia nigra of mice with Parkinson's disease," Journal of Xinxiang Medical University, vol. 31, no. 10, pp. 781-785, 2014.
24. Q. Wang, H. Zhang, M. Liu et al., "Influence of ginsenoside Rg1 in expressions of FADD and FLIP in substantia nigra of Parkinson's disease model mice," Journal of Jilin University Medicine Edition, vol. 40, no. 5, pp. 962-966, 2014.
25. Z. Yan, L. Wu, D. D. Xue, X. Q. Gao, and W. F. Chen, "Effects of Gesenoside Rg1 and insulin-like growth factor-I on dopaminergic neurons in Parkinson's disease mice," Acta Academic Medicine Qing Dao University, vol. 50, no. 4, pp. 283-285, 2014.
26. J. L. R. Liu, L. Li, Y. X. Zhang, and Z. F. Zhang, "The protective effect of Ginsenoside Rg1 on nerves in the mice model of Parkinson's disease," Clinical Medicine of China, vol. 24, no. 9, pp. 898-900, 2008.
27. G. J. Yang, J. P. Zhang, and Q. Y. Li, "Effect of ginsenoside Rg1 on neural stem cells in subventricular zone in modeled mice of Parkinson's disease," Sichuan Journal of Physiological Sciences, vol. 31, no. 1, pp. 17-19, 2009.
28. G. Z. Ji, The experimental research for evaluatingmice's dopaminergic neurons function by 99mTC-TRODAT-1 [Postgraduates' degree Thesis], 2008.
29. Q. Wang, H. Zheng, Z.-F. Zhang, and Y.-X. Zhang, "Ginsenoside Rg1 modulates COX-2 expression in the substantia nigra of mice with MPTP-induced Parkinson disease through the P38 signaling pathway," Journal of Southern Medical University, vol. 28, no. 9, pp. 1594-1598, 2008.
30. H. D. Yang, Neurprotective effects of Ginsenoside Rg1 on the dopaminergic neuron loss in the substantia nigra of MPTPtreated C57BL6 mice [Postgraduates' degree Thesis], 2007.
31. Y. C. Zhou, Y. G. Zhu, F. Fang, and L. M. Chen, "The influence of Ginsenoside Rg1 on JNK signaling cascade in PD mouse substantia nigra neurons," Acta Anatomica Sinica, vol. 34, no. 5, pp. 477-481, 2003.
32. G. G. Meng, Z. F. Zhang, X. J. Huan, Z. F. Wei, R. Li, and Y. X. Zhang, "Ginsenside Rgl protects the dopaminergic neurolls in substantia nigra against the apoptosis via downregulate the endoplasmic reticulum stress proteins expressions in the MPTP-induced Parkinson's disease mouse model," Chinese Journal of Anatomy, vol. 34, no. 3, pp. 358-361, 2011.
33. F. W. Yang, Influence of Ginsenside Rg1 on expressions of EphB6 and ephrinB1 in substantia nigra of mice with Parkinson's disease induced by MPTP [Postgraduates' degree Thesis], 2014.
34. Y. S. Wang, Y. X. Zhang, S. P. Wei, Z. F. Zhang, and Q. Y. Tian, "Influence of Ginsenoside Rg1 on p-c-Jun and COX-2 expression insubstantia nigra of the MPTP mouse model of subacute Parkinson's disease," Chinese Journal of Neuroanatomy, vol. 25, no. 4, pp. 432-436, 2009.
35. L. Xu, W. Chen, and M. Wong, "Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway," British Journal of Pharmacology, vol. 158, no. 3, pp. 738-748, 2009.
36. J. Jie, Study of neuroprotective effects of antioxidant Ginsenoside Rg1 on the Parkinson rats [Postgraduates' degree Thesis], 2010.
37. L. Xu, L.-X. Liu, and W.-F. Chen, "Effect and mechanism on dopamine contents of striatum in rat model of Parkinson's disease ginsenoside Rg1," Journal of Chinese Materia Medica, vol. 33, no. 15, pp. 1856-1859, 2008.
38. L. Z. M. Xu and W. F. Chen, "Neuroprotective effect of ginsenoside Rg1 on dopaminergic neurons and blocking effect of ICI182, 780," Journal of Shanxi Medical University, vol. 38, no. 8, pp. 677-681, 2007.
39. T. Zhou, G. Zu, X. Zhang et al., "Neuroprotective effects of ginsenoside Rg1 through the Wnt/β-catenin signaling pathway in both in vivo and in vitro models of Parkinson's disease," Neuropharmacology, vol. 101, pp. 480-489, 2016.
40. X.-C. Sun, X.-F. Ren, L. Chen, X.-Q. Gao, J.-X. Xie, and W.- F. Chen, "Glucocorticoid receptor is involved in the neuroprotective effect of ginsenoside Rg1 against inflammationinduced dopaminergic neuronal degeneration in substantia nigra," Journal of Steroid Biochemistry and Molecular Biology, vol. 155, pp. 94-103, 2016.
41. G. H. Guyatt, A. D. Oxman, V. Montori et al., "GRADE guidelines: 5. Rating the quality of evidence-publication bias," Journal of Clinical Epidemiology, vol. 64, no. 12, pp. 1277-1282, 2011.
42. E. D. M. Rooke, H. M. Vesterinen, E. S. Sena, K. J. Egan, and M. R. Macleod, "Dopamine agonists in animal models of Parkinson's disease: a systematic review and meta-analysis," Parkinsonism and Related Disorders, vol. 17, no. 5, pp. 313-320, 2011.
43. B. C. Kahan, S. Cro, C. J. Doré et al., "Reducing bias in openlabel trials where blinded outcome assessment is not feasible: strategies from two randomised trials," Trials, vol. 15, no. 1, article no. 456, 2014.
44. U. Held, "On the impact of sample size calculation and power in clinical research," Praxis, vol. 103, no. 20, pp. 1197-1201, 2014.
45. K. F. Schulz and D. A. Grimes, "Sample size calculations in randomised trials: mandatory and mystical," The Lancet, vol. 365, no. 9467, pp. 1348-1353, 2005.
46. D. G. Hackam, "Translating animal research into clinical benefit," British Medical Journal (Clinical Research Edition), vol. 334, no. 7586, pp. 163-164, 2007.
47. D. G. Hackam and D. A. Redelmeier, "Translation of research evidence from animals to humans," JAMA, vol. 296, no. 14, pp. 1727-1732, 2006.
48. Y. Takino, "Studies on the pharmacodynamics of ginsenoside-Rg1, -Rb1 and -Rb2 in rats," Yakugaku Zasshi, vol. 114, no. 8, pp. 550-564, 1994.
49. Y. Zhang, L. Lin, G.Y. Liu, J.X. Liu, and T. Li, "Pharmacokinetics and brain distribution of ginsenosides after administration of Sailuotong," China Journal of Chinese Materia Medica, vol. 39, no. 2, pp. 316-321, 2014 (Chinese).
50. H. Liu, J. Yang, F. Du et al., "Absorption and disposition of ginsenosides after oral administration of panax notoginseng extract to rats," Drug Metabolism and Disposition, vol. 37, no. 12, pp. 2290-2298, 2009.
51. 2 in the large intestine of rats," Chemical and Pharmaceutical Bulletin, vol. 38, no. 10, pp. 2859-2861, 1990.
52. X. X. Wen, "Treating 68 cases of tremble of Qixue Kuixu type with the Renshen Yangrong decoction," Clinical Journal of Chinese Medicine, vol. 5, no. 3, p. 67, 2013.
53. D. G. Wang, "Clinical observation of Ginseng Guipi decoction on elderly patients of deficiency of qi and blood type with Parkinson's disease," Guiding Journal of Traditional Chinese Medicine and Pharmacy, vol. 20, no. 6, pp. 126-127, 2014.
54. J. Wei, W. Yang, S. Yin, C. Wang, Y. Wang, and G. Zheng, "The quality of reporting of randomized controlled trials of electroacupuncture for stroke," BMC Complementary and Alternative Medicine, vol. 16, no. 1, article no. 512, 2016.